Physician profile
Joyce Tibbett
NPI 1881008290
$487.51
in general payments reported to CMS, 2019-2025
13 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.16 · 2020: $14.16 · 2021: $41.20 · 2022: $48.86 · 2023: $16.74 · 2024: $18.80 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $333.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $147.70 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.03 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $56.60 | 2021-2025 | |
| Insulet Corporation | $50.59 | 2025 | Omnipod |
| Lilly USA, LLC | $38.00 | 2024-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $20.25 | 2025 | Airsupra |
| Inspire Medical Systems, INC. | $19.84 | 2025 | Inspire |
| Abbvie INC. | $19.33 | 2025 | |
| Phathom Pharmaceuticals, INC. | $18.31 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $15.54 | 2025 | Gardasil 9, Capvaxive |
| Amgen INC. | $14.16 | 2020 | |
| Gilead Sciences, INC. | $13.22 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Tibbett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.